Pérez-Belmonte, Luis MSanz-Cánovas, JaimeGarcía de Lucas, María DRicci, MicheleAvilés-Bueno, BeatrizCobos-Palacios, LidiaPérez-Velasco, Miguel ALópez-Sampalo, AlmudenaBernal-López, M RosaJansen-Chaparro, SergioMiramontes-González, José PGómez-Huelgas, Ricardo2024-02-272024-02-272022-06-241664-2392http://hdl.handle.net/10668/20560http://hdl.handle.net/20.500.12105/18686The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months. A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.engVoRhttp://creativecommons.org/licenses/by/4.0/health statusheart failureobesitysemaglutidetype 2 diabetesDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesHeart FailureHumansObesityRetrospective StudiesAttribution 4.0 International358136291385103510.3389/fendo.2022.851035Frontiers in endocrinologyopen access